866-997-4948(US-Canada Toll Free)

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Sep 2017

Category :

Pharmaceutical

No. of Pages : 34 Pages

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)-Pipeline Review, H2 2017

Summary

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)-Cathepsin B (CatB) is an enzymatic protein belonging to the peptidase. It promotes hydrolysis of proteins with broad specificity for peptide bonds. It cleaves -Arg-Arg-|-Xaa bonds in small molecule substrates. In addition to being an endopeptidase, shows peptidyl-dipeptidase activity, liberating C-terminal dipeptides.

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) pipeline Target constitutes close to 9 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase I, Phase 0, Preclinical and Discovery stages are 1, 1, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Gastrointestinal, Immunology and Infectious Disease which include indications Alzheimer's Disease, Liver Fibrosis, Autoimmune Disorders, Breast Cancer, Cancer Pain, Ebolavirus Infections (Ebola Hemorrhagic Fever), Neuropathic Pain, Non-Alcoholic Steatohepatitis (NASH), Pancreatic Cancer, Primary Biliary Cirrhosis and Traumatic Brain Injury.

The latest report Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)-Pipeline Review, H2 2017, outlays comprehensive information on the Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)
- The report reviews Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)-Overview 6
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)-Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 12
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)-Therapeutics Assessment 14
Assessment by Mechanism of Action 14
Assessment by Route of Administration 15
Assessment by Molecule Type 16
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)-Companies Involved in Therapeutics Development 18
ALSP Inc 18
Oncomatryx Biopharma SL 18
Phelix Therapeutics LLC 18
Virobay Inc 19
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)-Drug Profiles 20
ALP-496-Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
CIBP-4-Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
Drugs to Inhibit Cathepsin B for Ebola Viral Infections-Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
OMTX-001-Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
Small Molecule to Inhibit Cathepsin B for Oncology-Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Small Molecules to Inhibit Cathepsin B for Alzheimer's Disease-Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
VBY-285-Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
VBY-376-Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
VBY-825-Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)-Dormant Products 30
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)-Product Development Milestones 31
Featured News & Press Releases 31
Apr 19, 2016: American Life Science Pharmaceuticals Obtains Patent 31
Jan 25, 2016: ALSP invited to Give Oral Presentation at the Keystone TBI Conference January 25-27 in Santa Fe, New Mexico 31
Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model 31
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 33
Disclaimer 34

List of Tables
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Indication, H2 2017 9
Number of Products under Development by Companies, H2 2017 10
Products under Development by Companies, H2 2017 11
Number of Products under Investigation by Universities/Institutes, H2 2017 12
Products under Investigation by Universities/Institutes, H2 2017 13
Number of Products by Stage and Mechanism of Actions, H2 2017 14
Number of Products by Stage and Route of Administration, H2 2017 15
Number of Products by Stage and Molecule Type, H2 2017 17
Pipeline by ALSP Inc, H2 2017 18
Pipeline by Oncomatryx Biopharma SL, H2 2017 18
Pipeline by Phelix Therapeutics LLC, H2 2017 19
Pipeline by Virobay Inc, H2 2017 19
Dormant Projects, H2 2017 30

List of Figures
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Top 10 Indications, H2 2017 9
Number of Products by Stage and Mechanism of Actions, H2 2017 14
Number of Products by Stage and Route of Administration, H2 2017 15
Number of Products by Molecule Types, H2 2017 16
Number of Products by Stage and Molecule Types, H2 2017 16

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *